Authors
Joffrey van Prehn, Elena Reigadas, Erik H Vogelzang, Emilio Bouza, Adriana Hristea, Benoit Guery, Marcela Krutova, Torbjorn Norén, Franz Allerberger, John E Coia, Abraham Goorhuis, Tessel M van Rossen, Rogier E Ooijevaar, Karen Burns, Bente R Scharvik Olesen, Sarah Tschudin-Sutter, Mark H Wilcox, Maria JGT Vehreschild, Fidelma Fitzpatrick, Ed J Kuijper
Publication date
2021/12/1
Journal
Clinical Microbiology and Infection
Volume
27
Pages
S1-S21
Publisher
Elsevier
Description
Scope
In 2009, the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) published the first treatment guidance document for Clostridioides difficile infection (CDI). This document was updated in 2014. The growing literature on CDI antimicrobial treatment and novel treatment approaches, such as fecal microbiota transplantation (FMT) and toxin-binding monoclonal antibodies, prompted the ESCMID study group on C. difficile (ESGCD) to update the 2014 treatment guidance document for CDI in adults.
Methods and Questions
Key questions on CDI treatment were formulated by the guideline committee and included: what is the best treatment for initial, severe, severe-complicated, refractory, recurrent and multiple recurrent CDI; what is the best treatment when no oral therapy is possible; can prognostic factors identify patients at risk for severe and recurrent CDI; and is there a place for CDI …
Total citations
Scholar articles
J van Prehn, E Reigadas, EH Vogelzang, E Bouza… - Clinical Microbiology and Infection, 2021